Intermittent androgen suppression
was first described in a report by Dr.
The researchers found that androgen suppression
therapy had a negative effect on vitality, which includes mood and energy.
According to the report, higher dose radiation (over 76-78 Gy) combined with androgen suppression
therapy is commonly used to treat prostate cancer.
In Germany, Plenaxis(R) is indicated to initiate hormonal castration in patients with advanced or metastatic, hormone-dependent prostate cancer, if androgen suppression
Potential benefits of intermittent androgen suppression
therapy in the treatment of prostate cancer: A systematic review of the literature.
A parallel study (RTOG 86-10) has shown that androgen suppression
given before and during radiotherapy improved outcome in patients with Gleason 2-6 disease.
The manuscript, Androgen Suppression
Adjuvant to Definitive Radiotherapy in Carcinoma of the Prostate - Long Term Results of Phase III RTOG 85-31, was published in the April 1, 2005 edition of the International Journal of Radiation Oncology Biology Physics, vol.
It covers areas such as: androgen suppression
, cytotoxic treatment
Duration of androgen suppression
in the treatment of prostate cancer.
New guidelines for the use of androgen suppression
and possible benefits from combinations with radiation therapy are described in this report.
Report Contents: Introduction Androgen Suppression
Prostate Cancer & Prevention New Standard of Care Prostate and Obesity Company profiles Disclaimer
While there is agreement about the need for androgen suppression
in hormone-sensitive prostate cancer, optimal testoster-one levels on ADT remains a matter of debate.
Different from other approved androgen suppression
therapies, Plenaxis(TM) is not characterized by a testosterone surge that can result in exacerbation of the disease.